[An experimental study of matrix metalloproteinase inhibitor BB-94 inhibits the invasion and metastasis of the human salivary adenoid cystic carcinoma in vitro and in vivo].
OBJECTIVE
To study the inhibitory effect of matrix metalloproteinase inhibitor BB-94 on the invasion and metastasis of salivary adenoid cystic carcinoma in vitro and in vivo.


METHODS
Reconstituted basement membrane invasion assay was used to evaluate invasive ability of cancer cells. Type IV collagenase was assessed by PAGE substrate zymography. In addition, the antimetastasis effect of the compound was studied in in vivo experiments using nude mice model of pulmonary metastasis with ACC-M line of human salivary adenoid cystic carcinoma.


RESULTS
BB-94, at the concentrations of 10 mumol/L and 100 mumol/L, suppressed the reconstituted basement invasion of ACC-M human salivary adenoid cystic carcinoma by 32.9%, 53.2% and reduced Type IV collagenase activities in the serum-free supernatant of the same cells. The pulmonary metastasis rate of the control and treated groups was 90.0% and 20.0%, respectively (P < 0.01). The lung weight of the control and treated groups was (0.2090 +/- 0.0667) g and (0.1532 +/- 0.0378) g, respectively (P < 0.05).


CONCLUSIONS
These results suggest that the matrix metalloproteinase inhibitor BB-94 has a strong inhibitory effect on invasion and metastasis of salivary adenoid cystic carcinoma.
Mao
L
L
Department of Oral Surgery, The First Clinical Hospital, Harbin Medical University, Harbin 150001, China.
Yu
S
S
Sun
K
K
D000818:Animals; D003528:Carcinoma, Adenoid Cystic / Q000556:secondary*; D004195:Disease Models, Animal; D005260:Female; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012466:Salivary Gland Diseases / Q000473:pathology*; D013876:Thiophenes / Q000627:therapeutic use*
D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D013876:Thiophenes; D010649:Phenylalanine; C080985:batimastat; D020782:Matrix Metalloproteinases